Alkermes (ALKS)
(Delayed Data from NSDQ)
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.59 USD
-0.52 (-1.92%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $26.52 -0.07 (-0.26%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALXN or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. ALKS: Which Stock Is the Better Value Option?
Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.
GILD vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ALKS: Which Stock Is the Better Value Option?
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes Reports Positive Data From Schizophrenia Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
by Zacks Equity Research
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
Alkermes Focuses on Pipeline, Depends on Partners for Funds
by Zacks Equity Research
Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.
Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's Depression Candidate Fails in Studies, Stock Down
by Zacks Equity Research
Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA
by Zacks Equity Research
The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 666.67% and 24.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO
Analysts Estimate Alkermes (ALKS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
by Zacks Equity Research
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
Alkermes Sinks as FDA Refuses to Approve Depression Drug
by Zacks Equity Research
Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).
What Makes Alkermes (ALKS) a New Buy Stock
by Zacks Equity Research
Alkermes (ALKS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CBM or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBM vs. ALKS: Which Stock Is the Better Value Option?
Biogen Begins Improved Dosing Regimen on Tysabri in Phase III
by Zacks Equity Research
Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.
Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug
by Zacks Equity Research
Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.
Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.